National Institute on Aging /Alzheimer's Association criteria for Mild Cognitive Impairment applied to chemotherapy treated breast cancer survivors.

Author(s): Gifford AR,  Lawrence JA,  Baker LD,  Balcueva EP,  Case D,  Craft S,  Curtis AE,  Griffin L,  Groteluschen DL,  Klepin HD,  Lesser GJ,  Messino MJ,  Naughton M,  Samuel TA,  Rapp S,  Sachs B,  Sink KM,  Williamson J,  Shaw EG

Journal: J Oncol Research

Date: 2017

Major Program(s) or Research Group(s): NCORP

PubMed ID: 29873324

PMC ID: PMC5985141

Abstract: Background: In this analysis we use the National Institute on Aging/Alzheimer's Association (NIA/AA) criteria to identify Mild Cognitive Impairment (MCI) in a sample of breast cancer survivors treated with chemotherapy. Methods: Sixty women ages 39-79 on a prospective clinical trial of donepezil were assessed at baseline using a battery of standardized/validated neurocognitive measures. Cognitive status was adjudicated to identify MCI by a panel of dementia experts. Results: Fifty percent were not cognitively impaired, 43% met the NIA/AA criteria for MCI, 2% had dementia, and 5% could not be classified. Discussion: In this sample, nearly half of breast cancer survivors met the NIA/AA criteria for MCI. We propose these criteria be used to define cancer-related Mild Cognitive Impairment (cMCI), providing a framework for conducting additional studies to further characterize cMCI and identify clinical, imaging, and genetic factors associated with the progression of cMCI to more advanced stages of cognitive impairment.